BLACK LION EDGE

EPIVYN

How does it work?

What is Apoptosis?

EPIVYN Licensing

Investors

EPIVYN Program

Cancer Laboratory

.........................................

Home » Epivyn Licensing

   EPIVYN Licensing Agreements with Black Lion Pharmaceuticals

Black Lion Pharmaceuticals is currently developing a network for product licensing for our novel anti-cancer drug EPIVYN which displays cancer killing effects similar and/or greater to other leading products including Methotrexate, Cisplatin and Doxorubicin. The superior action of EPIVYN is based on its ability to induce significant apoptosis in cancer cells at doses that illicit very low toxicity to normal cells. 

Black Lion Pharmaceuticals is the sole owner of the intellectual property, developmental biotechnology and patent of this novel revolutionary cancer drug. Our philosophy on the war of cancer is to expeditiously collaborate with other pharmaceutical and health organizations in order to fast track life saving products to cancer patients worldwide.   

Black Lion Pharmaceuticals is a privately held corporation that focuses exclusively in the development of drugs and molecules that are targeted to be future cancer treatment leaders and that will improve the quality of life of millions of patients that unfortunately suffer this disease worldwide.  

For more information regarding licensing of EPIVYN email us at info@blionpharma.com